Added reassurance

Q2 better than feared

Good cost control in Q2

Solid Q2 with promising outlook for H2

Good opportunities in a pressured sector

Hitting the trough

Positive sales momentum in Q2e

Arjo AB: 1 director

A director at Arjo AB bought 100,000 shares at 32.750SEK and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...

Decent player activity in Q2 to date

Early Q2 players up 1% vs Q1

Evolution (Buy, TP: SEK1100.00) - Play it right in fencing

Despite intact 2025 EBITDA margin guidance, a soft Q1 and near-term uncertainties made us cut our 2025–2027e EPS by c10%. The step-up of focus on regulated markets supports the long-term case, although it comes with costs near-term. We reiterate our BUY but have cut our target price to SEK1,100 (1,440). We expect buybacks, expansion, new games, and growth improvements to strengthen the story later in 2025.

Big Q1 disappointment, but exaggerated reaction

Arjo (Hold, TP: SEK35.00) - Soft start to 2025

Q1 sales were broadly in line, but adj. EBITDA was c8% below our forecast and c6% below consensus. The main differences came from higher operating expenses than expected as well as a slightly lower gross margin. Product sales were weak, but service/spare parts and rental saw stronger sales than expected, a mix that is generally negative for the margin trend. We reiterate our HOLD and have cut our target price to SEK35 (42).

Big sales miss, concerning growth numbers

Margin pressure in '25e

Sales ok, but higher opex in Q1

Heads-up for report 30 April

ALK-Abello (Buy, TP: DKK190.00) - Expecting solid start to the year

We expect a solid Q1 report, with likely c11% organic growth as well as good margin progress supporting the 2025 guidance. Based on its footprint, we see minimal effect in case of tariffs on pharmaceuticals, with the biggest risk coming from potential reciprocal ones from Europe. We reiterate our BUY and DKK190 target price.

Steady progress in Q1e

Evolution (Buy, TP: SEK1440.00) - Buying opportunity on our data

According to our tracker, Evolution’s daily average players grew by 10% QOQ in Q1, compared with our quarterly average Live revenue growth of 3% for 2025e. While still early, Q2 has started very strongly, with 12% QOQ player growth so far. In conclusion, our data signals strong underlying demand for Evolution’s products and a vital recovery after the H2 headwinds.